Birinapant (trade name: HDM-201) is a small molecule inhibitor produced by TetraLogic Pharmaceuticals Corporation. The chemical name of Birinapant is Diethyl N-(4-((2-(2-methyl-1H-indol-3-yl)ethyl)amino)-2-(phenylthio)phenyl)-2,2-dimethylmalonamide. Its molecular formula is C33H40N4O2S, its formula weight is 560.77g/mol, and its CAS number is 1260251-31-7.
Top Ten Keywords and Synonyms
According to a Google search for Birinapant, these are the top ten keywords related to it: "tumor necrosis factor", "TNF", "apoptosis", "cancer", "survivin", "small molecule inhibitor", "clinical trial", "chemotherapy", "solid tumors", and "non-Hodgkin's lymphoma".
Some of the Synonyms for Birinapant include Diethyl N-(4-((2-(1-methyl-1H-indol-3-yl)ethyl)amino)-2-(phenylthio) phenyl)-2,2-dimethylmalonamide, Compound 32, HDM-201, and TL32711.
Health Benefits of Birinapant
Birinapant is a promising anti-cancer agent due to its ability to selectively target tumor cells and induce apoptosis (programmed cell death). It works by inhibiting the activity of cellular proteins called IAPs (inhibitor of apoptosis proteins), which normally protect cancer cells from undergoing apoptosis. This can lead to the destruction of tumors and the prevention of cancer cell growth.
In pre-clinical studies, Birinapant has shown beneficial effects against a variety of cancer cell types, including breast, ovarian, pancreatic, prostate, and lung cancer cells. It has also been shown to increase the effectiveness of chemotherapy in some cases. Several clinical trials have been conducted to investigate the effectiveness of Birinapant in treating cancers such as non-Hodgkin's lymphoma, leukemia, and advanced solid tumors.
The molecular mechanism of Birinapant involves the inhibition of IAPs, which are proteins that bind to and inhibit enzymes called caspases that are involved in the process of apoptosis. By inhibiting IAPs, Birinapant promotes the activation of caspases and the elimination of cancer cells through apoptosis. Moreover, Birinapant can also stimulate the immune system to target cancer cells.
Safety of Birinapant
Studies of Birinapant have shown high tolerability at all dose levels tested in cancer patients. Birinapant is administered intravenously to patients and circulating levels of the drug are monitored, and dose reduction is recommended in the presence of toxicity.
The side effects of Birinapant are generally mild, with the most common side effects being injection site reactions, fatigue, and gastrointestinal disorders, such as nausea, vomiting, and diarrhea. Additionally, some patients have reported fever and chills after treatment.
The dosage of Birinapant varies depending on the type of cancer being treated and the stage of the disease. In clinical trials, doses ranging from 4mg/m2 to 16 mg/m2 are administered intravenously once or twice a week. The safety and efficacy of higher doses have not yet been established.
Birinapant has promising therapeutic potential in the treatment of several types of cancers. As a small molecule inhibitor, it can selectively target tumor cells for apoptosis and, in some cases, increase their sensitivity to chemotherapy. The safety and tolerability of Birinapant have been demonstrated in clinical trials, and ongoing research continues to provide further insights into its efficacy and safety profile. With more clinical trials, Birinapant may soon develop into a novel anti-cancer agent of great importance to modern medicine